CD44 and breast carcinoma: Accordingly, Creighton et al. reported an enrichment in the CD44+CD24− population in residual tumour tissue after endocrine therapy, compared with pretreated samples, in a cohort of 52 breast cancer patients in phase II clinical trials [100].